India's indigenous dengue vaccine, DengiAll, has entered final Phase 3 trials involving 10,000 volunteers DengiAll is a single-dose, tetravalent live-attenuated vaccine targeting all four dengue virus serotypes Phase 3 trials began in August 2024 across multiple dengue-endemic Indian cities with placebo controls